Alterations in the progenitor cell population follow recovery from myeloablative therapy and bone marrow transplantation
- PMID: 9197323
Alterations in the progenitor cell population follow recovery from myeloablative therapy and bone marrow transplantation
Abstract
In a previous study we showed that following recovery from bone marrow transplantation (BMT), there are persistent derangements in the clonogenic growth of hematopoietic progenitors and in the microenvironment. To characterize the abnormalities within the precursor cell population, selected BM CD34+ cells from 15 patients in remission from hematological malignancies who had received myeloablative therapy and grafts (eight allogeneic and seven autologous) were tested in dose-response studies with recombinant cytokines. Preconditioning for transplantation was accomplished with fractionated total body irradiation (fTBI) at 12 Gy, cyclophosphamide at 120 mg/kg and fractionated total lymphoid irradiation fTLI at 6 Gy. The median mononuclear cell number infused was 0.9 x 10(8)/kg (SD 0.31). At the time of BMT, the patient's median age was 26 (SD 8.65) years and eight were female. Grafts were studied at a median of 37 (SD 48.43) months from transplantation. The light density marrow population from the patients and controls was monocyte- and T-lymphocyte depleted; CD34+ precursors were then selected with immunomagnetic beads (median 90.2 and 92% blasts) and cultured in the progenitor cell assay at a cell density of 5 x 10(3) culture with incremental concentrations of recombinant human growth factors (rhGFs). BMT patients' cultures showed significantly lower colony scores at the lowest cytokine concentrations in both erythroid burst-forming units (BFU-Es) and erythroid colony forming units (CFU-Es) as well as in myeloid lineages; colony forming units-granulocyte macrophage (CFU-GM), and did not improve at the highest GF doses. No significant differences in the results were found between the autologous and allogeneic marrow sources. We conclude that following BMT, lineage restricted progenitors within the CD34+ population are significantly reduced, failing to recover even 8 years after transplantation.
Similar articles
-
Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.Exp Hematol. 1995 Dec;23(14):1661-6. Exp Hematol. 1995. PMID: 8542962
-
Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantation.Bone Marrow Transplant. 2002 Apr;29(7):557-62. doi: 10.1038/sj.bmt.1703512. Bone Marrow Transplant. 2002. PMID: 11979303
-
Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.Exp Hematol. 1997 Oct;25(11):1125-39. Exp Hematol. 1997. PMID: 9328449
-
Clonogenic hematopoietic progenitors and endogenous cytokine production in allogeneic bone marrow transplantation.J Hematother. 1993 Fall;2(3):343-5. doi: 10.1089/scd.1.1993.2.343. J Hematother. 1993. PMID: 7921994 Review.
-
Cell culture assessment of hematopoietic progenitors in bone marrow transplantation.J Hematother. 1993 Spring;2(1):19-25. doi: 10.1089/scd.1.1993.2.19. J Hematother. 1993. PMID: 7921963 Review.
Cited by
-
Telomere biology in hematopoiesis and stem cell transplantation.Blood Rev. 2011 Nov;25(6):261-9. doi: 10.1016/j.blre.2011.06.004. Epub 2011 Jul 20. Blood Rev. 2011. PMID: 21764192 Free PMC article. Review.
-
Translational research for bone marrow failure patients.Exp Hematol. 2022 Jan;105:18-21. doi: 10.1016/j.exphem.2021.11.004. Epub 2021 Nov 18. Exp Hematol. 2022. PMID: 34801643 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Medical